Bluejay Diagnostics Inc
BJDX0.706USD
-0.039-5.27%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
1.16MMarket Cap
LossP/E TTM
More Details of Bluejay Diagnostics Inc Company
Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes in critical care settings. It develops rapid tests using whole blood on its Symphony technology platform (Symphony), which consists of an analyzer and single-use protein detection cartridges that have the function of automatic stepwise feeding of reagent. The Symphony device is designed to produce laboratory-quality results in 20 minutes in critical care settings, including Intensive Care Units (ICUs) and Emergency Rooms (ERs). Its product candidate, the Symphony IL-6 test, is an immunoassay for the measurement of interleukin-6 (IL-6) to be used for the monitoring of disease progression in critical care settings. It is focused on pursuing the Symphony IL-6 test in the context of sepsis. IL-6 is a clinically established inflammatory biomarker, and is considered a 'first-responder', for the assessment of severity of infection and inflammation across many disease indications, including sepsis.
Bluejay Diagnostics Inc Info
Ticker SymbolBJDX
Company nameBluejay Diagnostics Inc
IPO dateNov 10, 2021
CEODey (Neil)
Number of employees7
Security typeOrdinary Share
Fiscal year-endNov 10
Address360 Massachusetts Avenue, Suite 203
CityACTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code01720
Phone19786310152
Websitehttps://bluejaydx.com/
Ticker SymbolBJDX
IPO dateNov 10, 2021
CEODey (Neil)
Company Executives of Bluejay Diagnostics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Donald R. Chase
Mr. Donald R. Chase
Independent Director
Independent Director
98.00
--
Ms. Svetlana Dey
Ms. Svetlana Dey
Director
Director
6.00
--
Mr. Douglas C. Wurth
Mr. Douglas C. Wurth
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Fred S. Zeidman
Mr. Fred S. Zeidman
Independent Director
Independent Director
--
--
Mr. Neil (Indranil) Dey
Mr. Neil (Indranil) Dey
President, Chief Executive Officer, Principal Executive Officer, Co-Founder, Principal Financial and Accounting Officer, Director
President, Chief Executive Officer, Principal Executive Officer, Co-Founder, Principal Financial and Accounting Officer, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Donald R. Chase
Mr. Donald R. Chase
Independent Director
Independent Director
98.00
--
Ms. Svetlana Dey
Ms. Svetlana Dey
Director
Director
6.00
--
Mr. Douglas C. Wurth
Mr. Douglas C. Wurth
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Fred S. Zeidman
Mr. Fred S. Zeidman
Independent Director
Independent Director
--
--
Mr. Neil (Indranil) Dey
Mr. Neil (Indranil) Dey
President, Chief Executive Officer, Principal Executive Officer, Co-Founder, Principal Financial and Accounting Officer, Director
President, Chief Executive Officer, Principal Executive Officer, Co-Founder, Principal Financial and Accounting Officer, Director
--
--
Revenue Breakdown
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Nov 20
Updated: Thu, Nov 20
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Intracoastal Capital, L.L.C.
9.65%
DRW Securities, LLC
3.29%
Sabby Management, LLC
1.63%
Armistice Capital LLC
0.38%
Tower Research Capital LLC
0.25%
Other
84.80%
Shareholders
Shareholders
Proportion
Intracoastal Capital, L.L.C.
9.65%
DRW Securities, LLC
3.29%
Sabby Management, LLC
1.63%
Armistice Capital LLC
0.38%
Tower Research Capital LLC
0.25%
Other
84.80%
Shareholder Types
Shareholders
Proportion
Corporation
9.67%
Investment Advisor
3.44%
Investment Advisor/Hedge Fund
1.86%
Hedge Fund
0.63%
Individual Investor
0.03%
Other
84.36%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
21
107.69K
6.48%
--
2025Q3
22
107.69K
7.87%
-5.14K
2025Q2
22
108.63K
1.16%
+96.42K
2025Q1
23
12.21K
4.22%
-11.19K
2024Q4
24
12.14K
4.03%
-17.82K
2024Q3
26
29.96K
1.04%
+23.88K
2024Q2
26
6.08K
2.15%
+5.00K
2024Q1
24
1.08K
7.93%
+549.00
2023Q4
24
499.00
2.34%
+441.00
2023Q3
25
58.00
1.55%
+36.00
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Sabby Management, LLC
96.03K
6.43%
+96.03K
--
Jun 30, 2025
Armistice Capital LLC
6.95K
0.47%
+6.95K
--
Sep 30, 2024
Tower Research Capital LLC
2.27K
0.15%
+533.00
+30.65%
Jun 30, 2025
Geode Capital Management, L.L.C.
4.20K
0.28%
--
--
Aug 31, 2025
Lana Management & Business Research International LLC
511.00
0.03%
--
--
May 02, 2025
Wurth (Douglas Clark)
414.00
0.03%
--
--
May 02, 2025
Chase (Donald R)
98.00
0.01%
--
--
May 02, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Nov 13, 2024
Merger
50→1
Nov 13, 2024
Merger
50→1
Nov 13, 2024
Merger
50→1
Nov 13, 2024
Merger
50→1
Jun 17, 2024
Merger
8→1
Jun 17, 2024
Merger
8→1
Date
Type
Ratio
Nov 13, 2024
Merger
50→1
Nov 13, 2024
Merger
50→1
Nov 13, 2024
Merger
50→1
Nov 13, 2024
Merger
50→1
Jun 17, 2024
Merger
8→1
Jun 17, 2024
Merger
8→1
Jun 17, 2024
Merger
8→1
Jun 17, 2024
Merger
8→1
Jul 21, 2023
Merger
20→1
Jul 21, 2023
Merger
20→1
View more
FAQs
Who are the top five shareholders of Bluejay Diagnostics Inc?
The top five shareholders of Bluejay Diagnostics Inc are:
Sabby Management, LLC holds 96.03K shares, accounting for 6.43% of the total shares.
Armistice Capital LLC holds 6.95K shares, accounting for 0.47% of the total shares.
Tower Research Capital LLC holds 2.27K shares, accounting for 0.15% of the total shares.
Geode Capital Management, L.L.C. holds 4.20K shares, accounting for 0.28% of the total shares.
Lana Management & Business Research International LLC holds 511.00 shares, accounting for 0.03% of the total shares.
Sabby Management, LLC holds 96.03K shares, accounting for 6.43% of the total shares.
Armistice Capital LLC holds 6.95K shares, accounting for 0.47% of the total shares.
Tower Research Capital LLC holds 2.27K shares, accounting for 0.15% of the total shares.
Geode Capital Management, L.L.C. holds 4.20K shares, accounting for 0.28% of the total shares.
Lana Management & Business Research International LLC holds 511.00 shares, accounting for 0.03% of the total shares.
What are the top three shareholder types of Bluejay Diagnostics Inc?
The top three shareholder types of Bluejay Diagnostics Inc are:
Intracoastal Capital, L.L.C.
DRW Securities, LLC
Sabby Management, LLC
Intracoastal Capital, L.L.C.
DRW Securities, LLC
Sabby Management, LLC
How many institutions hold shares of Bluejay Diagnostics Inc (BJDX)?
As of 2025Q4, 21 institutions hold shares of Bluejay Diagnostics Inc, with a combined market value of approximately 107.69K, accounting for 6.48% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -1.39%.
What is the biggest source of revenue for Bluejay Diagnostics Inc?
In FY2023, the -- business generated the highest revenue for Bluejay Diagnostics Inc, amounting to -- and accounting for --% of total revenue.
